NCT06805929

Brief Summary

Our study purpose is to evaluate the predictive power of various clinical, neurophysiological, and neuroimaging biomarkers-acquired and analyzed using advanced and integrated techniques-on motor functional recovery and disability post-stroke. The goal is to construct an integrated individual biomarker algorithm with a high predictive value for outcomes.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
26mo left

Started Jun 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress73%
Jun 2020Jun 2028

Study Start

First participant enrolled

June 15, 2020

Completed
4.6 years until next milestone

First Submitted

Initial submission to the registry

January 28, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 3, 2025

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2027

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2028

Last Updated

February 7, 2025

Status Verified

January 1, 2025

Enrollment Period

7.5 years

First QC Date

January 28, 2025

Last Update Submit

February 4, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • change in arm Fugl-Meyer score

    assess the predictive power of biomarkers, individually or in combination, on the Fugl-Meyer Upper Limb Motor Scale (FM-UL) score at two months post-rehabilitation admission and at 4-6 months post-discharge

    at T0 (from 14 to 30 days post-stroke), T1 (after 2 months of intensive rehabilitation treatment) and T2 (4-6 months after discharge).

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study will be conducted in the Neuromotor Rehabilitation Units (Modules A-B-C) of IRCCS San Raffaele Pisana, Rome, Italy

You may qualify if:

  • First stroke in the middle cerebral artery territory.
  • Ischemic or hemorrhagic stroke (7-30 days post-acute event).
  • Upper limb plegia or paresis.
  • Both genders, aged \>18 years.
  • Ability to provide informed consent by the patient or caregiver/responsible relative.

You may not qualify if:

  • Previous stroke.
  • Stroke in territories other than the middle cerebral artery.
  • Inability to provide informed consent.
  • Contraindications to TMS or MRI.
  • History of cancer in the past two years.
  • Presence of other neurological conditions interfering with biomarkers

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IRCCS San Raffaele

Roma, Italy, 00163, Italy

RECRUITING

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Central Study Contacts

Domenica Le Pera, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 28, 2025

First Posted

February 3, 2025

Study Start

June 15, 2020

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

June 30, 2028

Last Updated

February 7, 2025

Record last verified: 2025-01

Data Sharing

IPD Sharing
Will not share

Locations